PDGFRB and neoplasm: In our previous report [25], we used a nuclease-resistant internalizing RNA aptamer, named Gint4.T, to bind and inhibit the platelet-derived growth factor β receptor (PDGFRβ) [32], and then designed an AsiC (Gint4.T-STAT3) for the delivery of a STAT3 siRNA to GBM cells, inhibiting tumour cell growth.